doi: 10.3389/fnins.2019.00629 65
Circulating microparticle subpopulations in systemic lupus erythematosus are affected by disease activity
Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD
Adults who have a BMI of 27 or higher and also have at least one weight-related health condition, such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea
The platform itself is not a healthcare provider
and (iv) recognize revenue when or as performance obligations are satisfied